Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Nanjing Medical University

Status: Unknown

Conditions: Aneurysmal Subarachnoid Hemorrhage

Treatments: Drug: Antiplatelet Drug

Study type: Observational

Funder types: Other

Identifiers

NCT04548401

aSAH016

Details and patient eligibility

About

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Patients with SAH in whom the aneurysm was proven by conventional angiography; 2. Baseline Hunt-Hess grade I-III; 3. patients received endovascular treatment

Exclusion criteria

• 1. Hunt-Hess grade IV-V; 2. Non-aneurysmal SAH; 3. Dementia in other diseases; 4. Lacking of 6-8 month MoCA evaluation.

Trial design

200 participants in 2 patient groups

Antiplatelet-N group

Description:

Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy

Antiplatelet-Y group

Description:

Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor)

Treatment:

Drug: Antiplatelet Drug